Who
Mahkam Zanganeh
Director
Company insider
Files Form 4 as: Co-Chief Executive Officer, Summit Therapeutics; Director, Pulse Biosciences; Chief Operating Officer, Pharmacyclics.
In numbers
- Trades disclosed
- 185
- Buys
- 32
- Sells
- 8
- Bought
- $170.2M
- Sold
- $23.0M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 13 Dec 2010
- Last trade
- 12 Jun 2026
- Last filed
- 15 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Jun 2026filed 12 Jun 2026 | SMMT Summit TherapeuticsBiotechnology | SEC FORM 4 Bought | $50.0M3,810,000 at $13.12 | filing |
| 12 Jun 2026filed 12 Jun 2026 | SMMT Summit TherapeuticsBiotechnology | SEC FORM 4 Bought | $50.0M3,810,000 at $13.12 | filing |
| 11 Jun 2026filed 15 Jun 2026 | PLSE Pulse Biosciencesoption or derivative · Medical Devices | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | PLSE Pulse Biosciencesoption or derivative · Medical Devices | SEC FORM 4 Code A | —14,504 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | PLSE Pulse Biosciencesoption or derivative · Medical Devices | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | PLSE Pulse Biosciencesoption or derivative · Medical Devices | SEC FORM 4 Code A | —14,504 at $0.00 | filing |
| 4 Jun 2026filed 4 Jun 2026 | SMMT Summit TherapeuticsBiotechnology | SEC FORM 4 Bought | $1.5M100,000 at $14.60 | filing |
| 4 Jun 2026filed 4 Jun 2026 | SMMT Summit TherapeuticsBiotechnology | SEC FORM 4 Bought | $1.5M100,000 at $14.60 | filing |
| 2 Jan 2026filed 6 Jan 2026 | SMMT Summit Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $98K11,232 at $8.76 | filing |
| 2 Jan 2026filed 6 Jan 2026 | SMMT Summit Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $98K11,232 at $8.76 | filing |
| 21 Oct 2025filed 23 Oct 2025 | SMMT Summit TherapeuticsBiotechnology | SEC FORM 4 Code A | $5.0M266,808 at $18.74 | filing |
| 21 Oct 2025filed 23 Oct 2025 | SMMT Summit TherapeuticsBiotechnology | SEC FORM 4 Bought | $500K26,680 at $18.74 | filing |
| 21 Oct 2025filed 23 Oct 2025 | SMMT Summit TherapeuticsBiotechnology | SEC FORM 4 Code A | $262.0M13,980,789 at $18.74 | filing |
| 11 Sep 2025filed 11 Sep 2025 | SMMT Summit TherapeuticsBiotechnology | SEC FORM 4 Bought | $90K5,000 at $18.07 | filing |
| 10 Sep 2025filed 11 Sep 2025 | SMMT Summit TherapeuticsBiotechnology | SEC FORM 4 Bought | $5.9M333,394 at $17.68 | filing |
| 15 Aug 2025filed 19 Aug 2025 | PLSE Pulse Biosciencesoption or derivative · Medical Devices | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 15 Aug 2025filed 19 Aug 2025 | PLSE Pulse Biosciencesoption or derivative · Medical Devices | SEC FORM 4 Code A | —24,134 at $0.00 | filing |
| 30 May 2025filed 2 Jun 2025 | SMMT Summit Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —74,545 at $0.00 | filing |
| 30 May 2025filed 2 Jun 2025 | SMMT Summit TherapeuticsBiotechnology | SEC FORM 4 Code M | $197K74,545 at $2.64 | filing |
| 29 Apr 2025filed 1 May 2025 | SMMT Summit Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,040,000 | filing |
News
No headline names them, or the companies they trade most, lately.